Anticancer agent 230
Anticancer agent 230 (example 65) is a caseinolytic protease P (ClpP) activator with anticancer activity. Anticancer agent 230 is able to induce the degradation of mitochondrial proteins in SUM159 and MDA-MB-231 triple-negative breast cancer cells in a time-dependent manner[1].
Product Specifications
CAS Number
2485052-87-5
UNSPSC
12352005
Target
ClpP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-230.html
Purity
99.97
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
N#CC1=CC=CC(CN(C2)CCC(N=CN3CC4=CC=C(Cl)C=C4)=C2C3=O)=C1
Molecular Formula
C22H19ClN4O
Molecular Weight
390.87
References & Citations
[1]Preparation of tetrahydropyrido[4,3-d]pyrimidine-2,4-dione analogs useful in the treatment of cancers and in modulating the activity of caseinolytic protease p function. United States, US20230339947 A1. 2023-10-26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
033762-ML490 100 µL
CENPA, ID (CENPA, Histone H3-like centromeric protein A, Centromere autoantigen A, Centromere protein A) (MaxLight 490) discontinued
Sign In for Pricing
View Details 
